It's nearly mid-2022, and the combined company ICON has effectively utilized its expanded operations to transform clinical trials and accelerate bio-pharma customers' commercial success by creating much-needed medicines and medical equipments. Presently, the company holds a 38,000-employee base serving 46 nations along with focused services for the Asia Pacific and Latin America regions. Adding to such accomplishments, Dr. Steve Cutler, CEO of ICON, proudly claims, "as we continue to transform into the world's largest and most comprehensive healthcare intelligence organization, our world-class team has successfully aided the development of 30 customer drug and device approvals, including breakthrough COVID-19 vaccines and therapies."
Amidst the pandemic, ICON also combined with Pfizer— one of their biggest clients—to run a large-scale trial of the Pfizer-BioNTech Covid-19 vaccine. Moreover, using digital technologies, the firm conducted remote monitoring and on-site trials across 153 sites in Europe and America to recruit more than 44,000 trial participants over a four-month period.
Along with the groundbreaking services during the pandemic, ICON has jointly operated with the NetApp Ecosystem, which has accelerated data-driven clinical trials and introduced revolutionary revenue models for clinical data storage. Leveraging data, it has also benefited faster medicine and therapy delivery to market in a more cost-effective manner.
Icon: Where Quality Meets Quantity
Owing to such remarkable developments, ICON has been granted several prestigious titles—2022 Forbes’s best large employers, Scrip awards for best CRO 2021, Platinum awards for creative digital services and patient recruitment services, to name a few.
Besides ICON's revolutionary offerings, the top-notch quality standers serve as its key differentiators. It's quality management system ensures that all the services are performed to the highest ethical standards adhering to every relevant regulatory requirement, and contractual obligation, making them a trusted choice for clients. As a result, the company currently possesses a remarkable track record of successful audits—2650 sponsor audits, 10,000 internal audits, and more than 80 regulatory inspections.
Furthermore, with ICON's in-house quality assurance initiatives, their quality assurance department also provides stand-alone services to support clients in developing, implementing, and maintaining quality management systems to ensure the highest standards of Pharmacovigilance regulations.
As we continue to transform into the world's largest and most comprehensive healthcare intelligence organization, our world-class team has successfully aided the development of 30 customer drug and device approvals, including breakthrough COVID vaccines and therapies
Moving ahead, ICON look forward to expanding its service diversity by sticking to its primary objective: to help clients accelerate the development of drugs and devices that save lives and improve quality of life. "We are well-positioned to lead the market as the healthcare intelligence partner of choice in clinical development," concludes Cutler.